Barclays
ABCL icon

Barclays’s AbCellera Biologics ABCL Stock Holding History

Barclays’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$173K Buy
49,474
+15,927
+47% +$57.3K ﹤0.01% 3776
2025
Q4 		$115K Buy
33,547
+2,649
+9% +$11.8K ﹤0.01% 4541
2025
Q3 		$155K Sell
30,898
-12,130
-28% -$53.5K ﹤0.01% 4440
2025
Q2 		$148K Buy
43,028
+1,133
+3% +$2.82K ﹤0.01% 4463
2025
Q1 		$93.4K Buy
41,895
+3,544
+9% +$10.2K ﹤0.01% 4432
2024
Q4 		$112K Buy
38,351
+16,058
+72% +$44.7K ﹤0.01% 4568
2024
Q3 		$58K Buy
22,293
+1,465
+7% +$4.06K ﹤0.01% 4714
2024
Q2 		$61.7K Sell
20,828
-151,530
-88% -$573K ﹤0.01% 4123
2024
Q1 		$781K Buy
172,358
+51,701
+43% +$264K ﹤0.01% 3307
2023
Q4 		$689K Buy
120,657
+99,671
+475% +$462K ﹤0.01% 3687
2023
Q3 		$96.5K Sell
20,986
-504,978
-96% -$3.07M ﹤0.01% 3615
2023
Q2 		$3.4M Buy
525,964
+5,443
+1% +$37.1K ﹤0.01% 1585
2023
Q1 		$3.92M Buy
520,521
+203,493
+64% +$1.85M ﹤0.01% 1714
2022
Q4 		$3.21M Buy
317,028
+80,630
+34% +$931K ﹤0.01% 1931
2022
Q3 		$2.34M Sell
236,398
-4,830
-2% -$53K ﹤0.01% 1640
2022
Q2 		$2.57M Sell
241,228
-6,842
-3% -$57.9K ﹤0.01% 1676
2022
Q1 		$2.42M Buy
+248,070
New +$2.35M ﹤0.01% 1726

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's ABCL Position: Q1 2026 in Review

Barclays increased its AbCellera Biologics (ABCL) stake by 47% in Q1 2026, buying an estimated $57.3K and bringing the position to 49,474 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #3776.

Barclays first reported a position in ABCL in Q1 2022 and has held it in 17 quarters since. The position peaked at $3.92M in Q1 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Barclays held 49,474 shares of AbCellera Biologics worth $173K as of Q1 2026.
  • Barclays bought 15,927 AbCellera Biologics shares in Q1 2026, an estimated $57.3K.
  • AbCellera Biologics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3776 holding.
  • Barclays first reported a position in AbCellera Biologics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's AbCellera Biologics position peaked at $3.92M in Q1 2023.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.